Autor: |
Laube, A., Fuhrmann, S., Peczynski, C., Boumendil, A., Michel, E., Finel, H., Galimard, J., Beauvais, D., Daskalakis, M., Novak, U., Kröger, N., Stelljes, M., von Tresckow, B., Wulf, G. G., Dreger, P., Sureda, A., Schmitz, N., Glaß, B. |
Předmět: |
|
Zdroj: |
Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p454-456, 3p |
Abstrakt: |
B Conclusion: b With a 51% OS-rate at 12 months CART seem to be a very effective therapeutic option in heavily pre-treated r/r PCNSL or SCNSL, particularly for pts being refractory to prior therapy. Pts with involvement of the CNS were excluded from most CART trials; however, anecdotal reports suggest that CART might be an effective treatment option for such pts. B Introduction: b The prognosis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and involvement of the central nervous system (CNS) remains dismal. [Extracted from the article] |
Databáze: |
Complementary Index |
Externí odkaz: |
|